Cargando…

The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus

Objective: Intestinal inflammation triggers postoperative ileus (POI), commonly seen after abdominal surgery and characterized by impaired gastrointestinal transit; when prolonged, this leads to increased morbidity. Hydrogen sulfide (H(2)S) is recognized as an important mediator of many (patho)physi...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Dingenen, Jonas, Pieters, Leen, Vral, Anne, Lefebvre, Romain A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391894/
https://www.ncbi.nlm.nih.gov/pubmed/30842737
http://dx.doi.org/10.3389/fphar.2019.00116
_version_ 1783398384321691648
author Van Dingenen, Jonas
Pieters, Leen
Vral, Anne
Lefebvre, Romain A.
author_facet Van Dingenen, Jonas
Pieters, Leen
Vral, Anne
Lefebvre, Romain A.
author_sort Van Dingenen, Jonas
collection PubMed
description Objective: Intestinal inflammation triggers postoperative ileus (POI), commonly seen after abdominal surgery and characterized by impaired gastrointestinal transit; when prolonged, this leads to increased morbidity. Hydrogen sulfide (H(2)S) is recognized as an important mediator of many (patho)physiological processes, including inflammation, and is now investigated for anti-inflammatory application. Therefore, the aim of this study was to investigate the effect of the H(2)S-releasing naproxen derivative ATB-346, developed to reduce gastrointestinal injury by naproxen, and the slow-release H(2)S donor GYY4137 on intestinal inflammation and delayed gastrointestinal transit in murine POI. Methods: C57Bl6J mice were fasted for 6 h, anesthetized and after laparotomy, POI was induced by compressing the small intestine with two cotton applicators for 5 min (intestinal manipulation; IM). GYY4137 (50 mg/kg, intraperitoneally), ATB-346 (16 mg/kg, intragastrically) or naproxen (10 mg/kg, intragastrically) were administered 1 h before IM. At 24 h postoperatively, gastrointestinal transit was assessed via fluorescent imaging, and mucosa-free muscularis segments were prepared for later analysis. Inflammatory parameters and activity of inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX)-2 were measured. Histological examination of whole tissue sections was done on hematoxylin-eosin stained slides. Results: Pre-treatment with GYY4137 (geometric center; GC: 7.6 ± 0.5) and ATB-346 (GC: 8.4 ± 0.3) prevented the delayed transit induced by IM (GC: 3.6 ± 0.5 vs. 9.0 ± 0.4 in non-operated controls) while naproxen only partially did (GC: 5.9 ± 0.5; n = 8 for all groups). GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1β and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels. All treatments significantly reduced the increase in COX-2 activity caused by IM, whereas only GYY4137 significantly reduced the increase in iNOS activity. Naproxen treatment caused significant histological damage of intestinal villi. Conclusion: The study shows that naproxen partially prevents POI, probably through its inhibitory effect on COX-2 activity. Both ATB-346 and GYY4137 were more effective, the result with GYY4137 showing that H(2)S per se can prevent POI.
format Online
Article
Text
id pubmed-6391894
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63918942019-03-06 The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus Van Dingenen, Jonas Pieters, Leen Vral, Anne Lefebvre, Romain A. Front Pharmacol Pharmacology Objective: Intestinal inflammation triggers postoperative ileus (POI), commonly seen after abdominal surgery and characterized by impaired gastrointestinal transit; when prolonged, this leads to increased morbidity. Hydrogen sulfide (H(2)S) is recognized as an important mediator of many (patho)physiological processes, including inflammation, and is now investigated for anti-inflammatory application. Therefore, the aim of this study was to investigate the effect of the H(2)S-releasing naproxen derivative ATB-346, developed to reduce gastrointestinal injury by naproxen, and the slow-release H(2)S donor GYY4137 on intestinal inflammation and delayed gastrointestinal transit in murine POI. Methods: C57Bl6J mice were fasted for 6 h, anesthetized and after laparotomy, POI was induced by compressing the small intestine with two cotton applicators for 5 min (intestinal manipulation; IM). GYY4137 (50 mg/kg, intraperitoneally), ATB-346 (16 mg/kg, intragastrically) or naproxen (10 mg/kg, intragastrically) were administered 1 h before IM. At 24 h postoperatively, gastrointestinal transit was assessed via fluorescent imaging, and mucosa-free muscularis segments were prepared for later analysis. Inflammatory parameters and activity of inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX)-2 were measured. Histological examination of whole tissue sections was done on hematoxylin-eosin stained slides. Results: Pre-treatment with GYY4137 (geometric center; GC: 7.6 ± 0.5) and ATB-346 (GC: 8.4 ± 0.3) prevented the delayed transit induced by IM (GC: 3.6 ± 0.5 vs. 9.0 ± 0.4 in non-operated controls) while naproxen only partially did (GC: 5.9 ± 0.5; n = 8 for all groups). GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1β and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels. All treatments significantly reduced the increase in COX-2 activity caused by IM, whereas only GYY4137 significantly reduced the increase in iNOS activity. Naproxen treatment caused significant histological damage of intestinal villi. Conclusion: The study shows that naproxen partially prevents POI, probably through its inhibitory effect on COX-2 activity. Both ATB-346 and GYY4137 were more effective, the result with GYY4137 showing that H(2)S per se can prevent POI. Frontiers Media S.A. 2019-02-20 /pmc/articles/PMC6391894/ /pubmed/30842737 http://dx.doi.org/10.3389/fphar.2019.00116 Text en Copyright © 2019 Van Dingenen, Pieters, Vral and Lefebvre. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Van Dingenen, Jonas
Pieters, Leen
Vral, Anne
Lefebvre, Romain A.
The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title_full The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title_fullStr The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title_full_unstemmed The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title_short The H(2)S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H(2)S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus
title_sort h(2)s-releasing naproxen derivative atb-346 and the slow-release h(2)s donor gyy4137 reduce intestinal inflammation and restore transit in postoperative ileus
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391894/
https://www.ncbi.nlm.nih.gov/pubmed/30842737
http://dx.doi.org/10.3389/fphar.2019.00116
work_keys_str_mv AT vandingenenjonas theh2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT pietersleen theh2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT vralanne theh2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT lefebvreromaina theh2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT vandingenenjonas h2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT pietersleen h2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT vralanne h2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus
AT lefebvreromaina h2sreleasingnaproxenderivativeatb346andtheslowreleaseh2sdonorgyy4137reduceintestinalinflammationandrestoretransitinpostoperativeileus